Pacira BioSciences Inc 2026年季度报告

FORM10-Q PACIRA BIOSCIENCES,INC. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes☒ As of April29, 2026, 39,347,924 shares of the registrant’s common stock, $0.001 par value per share, were outstanding. PACIRA BIOSCIENCES,INC.QUARTERLY REPORT ON FORM 10-Q TABLE OF CONTENTS PARTI. FINANCIAL INFORMATION Item1.Legal Proceedings48Item1A.Risk Factors48 PACIRA BIOSCIENCES,INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY Pacira BioSciences, Inc. | Q12026Quarterly Report on Form 10-Q | 5 PACIRA BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1—DESCRIPTION OF BUSINESS Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) deliver innovative, non-opioid paintherapies to transform the lives of patients. The Company’s long-acting, local analgesic, EXPAREL(bupivacaine liposome injectable® suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and theUnited Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drugdelivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time.EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, andpostsurgical regional analgesia in adults via (i) an interscalene brachial plexus block in adults; (ii) a sciatic nerve block in the poplitealfossa; or (iii) an adductor canal block in adults for postsurgical pain management (the safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks other than an interscalene brachial plexus nerveblock, a sciatic nerve block in the popliteal fossa, and an adductor canal block). In November 2021, the Company acquired FlexionTherapeutics, Inc., or Flexion (the “Flexion Acquisition”), and added ZILRETTA(triamcinolone acetonide extended-release® injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint)injection indicated for the management of osteoarthritis, or OA, knee pain. In April 2019, the Company added iovera ° to itscommercial offering with the acquisition of MyoScience, Inc., or MyoScience, (the “MyoScience Acquisition”). The iovera° system isa handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of coldtemperature to a targeted nerve. The Company is also advancing two Phase 2 clinical programs—PCRX-201 (enekinragene® Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition fromlarger companies and potential generic entrants, reliance on revenue from three products, reliance on a limited number of wholesalers,reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third- NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accountingprinciples in the United States of America, or GAAP, and in accordance with the rulesand regulations of the United States Securitiesand Exchange Commission, for interim reporting. Pursuant to these rulesand regulations, certain information and footnote disclosures The condensed consolidated financial statements at March31, 2026, and for the three-month periods ended March31, 2026 and2025, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion ofmanagement, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensedconsolidated balance sheet at December3